McCurrach, M. E., Connor, T. M., Knudson, C. M., Korsmeyer, S. J., Lowe, S. W. (March 1997) bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 94 (6). pp. 2345-9. ISSN 0027-8424
Preview |
PDF
Lowe_PNAS_1997.pdf - Published Version Download (307kB) | Preview |
Abstract
Inactivation of p53-dependent apoptosis promotes oncogenic transformation, tumor development, and resistance to many cytotoxic anticancer agents. p53 can transcriptionally activate bax, a bcl-2 family member that promotes apoptosis. To determine whether bax is required for p53-dependent apoptosis, the effects of bax deficiency were examined in primary fibroblasts expressing the E1A oncogene, a setting where apoptosis is dependent on endogenous p53. We demonstrate that bax can function as an effector of p53 in chemotherapy-induced apoptosis and contributes to a p53 pathway to suppress oncogenic transformation. Furthermore, we show that additional p53 effectors participate in these processes. These p53-controlled factors act synergistically with Bax to promote a full apoptotic response, and their action is suppressed by the Bcl-2 and E1B 19K oncoproteins. These studies demonstrate that Bax is a determinant of p53-dependent chemosensitivity and illustrate how p53 can promote apoptosis by coordinating the activities of multiple effectors.
Actions (login required)
![]() |
Administrator's edit/view item |